12/09/2024
Overcoming Analytical Challenges in Liraglutide & Semaglutide Analysis
Glucagon-like peptide-1 (GLP-1) analogues, including Liraglutide and Semaglutide, have emerged as key therapeutic agents for the management of type II diabetes mellitus and obesity. However, the accurate quantification of these peptides in biological matrices presents significant analytical challenges. These challenges stem from the large molecular size of the peptides, their suboptimal ionization efficiency in mass spectrometry, and inherent issues related to sensitivity and sample preparation. The incorporation of a fatty acid moiety in these peptides further exacerbates these difficulties by increasing hydrophobicity and non-specific binding.
The work presented at the 10th EBF Young Scientist Symposium highlights the analytical challenges of developing UPLC/MS/MS methodologies for the extraction and quantification of Liraglutide and Semaglutide in plasma, while also outlining the strategies employed to solve them.
You may find below the poster for your ready reference:
MORE NEWS
Peptides Series: Understanding Therapeutic Peptides
Therapeutic peptides are transforming modern medicine thanks to their unique advantages over traditional drug therapies. Their molecular structure and biological properties allow them to achieve effects like natural molecules in the body, enabling targeted action with fewer risks of off-target effects.
The visit of the Mayor of Barcelona, Jaume Collboni, to Anapharm Bioanalytics
Last Friday, January 10th 2025, we had the honor of welcoming the Mayor of Barcelona, Jaume Collboni, to our facilities. His visit was a special opportunity for us to showcase the work we do at Anapharm Bioanalytics and to reaffirm our commitment to innovation in the field of bioanalysis.
Overcoming Matrix Effects in the Analysis of Lipophilic Compounds
At the 10th EBF Young Scientist Symposium, we highlighted the complexities of analysing Fucoxanthin derivatives and demonstrated how innovative approaches, such as 2D Chromatography, can overcome these obstacles.